PK/PD of P2Y12 Inhibitors in PCI for AMI

Phase 4, open-label trial of prasugrel, ticagrelor and clopidogrel in acute myocardial infarction (AMI) (6 arms), sponsored by The Royal Wolverhampton NHS Trust. Primary endpoints: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Pharmacokinetic Quantification of Plasma Concentration of Clopidogrel and Prasugrel Active Metabolite and Ticagrelor Parent Compound and Active Metabolite. Started Mar 2015; status: completed.